Medpace MEDP · NASDAQ
$669.20 +2.33% (+$15.24)
Summary
79 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 28% a year over the last 3 years.
- Out of every 100 USD of revenue, 18 USD is left as net profit.
- It earns 62 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $705.3M against $146.0M.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 35.2 USD for 1 USD of yearly profit. Over the last five years it was 34.4 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 20% a year. For the next fiscal year analysts expect revenue to grow by 13%. Earnings per share grew by 28% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 71 USD
- Sales and administration 7.8 USD
- Taxes and other 3.1 USD
- Net profit 18 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 18 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 15
- Sell 0
Today's price within the analysts' price targets
The average target of $637.67 is 4.7% below today's price. 21% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Oncology 30%
- Metabolic 29%
- Other 16%
- Central Nervous System 10%
- Cardiology 9.5%
- Other 5.3%
By region
The company reports no revenue by region.
Oncology brings in 30% of revenue. Metabolic grew fastest, by 47% a year.
Segments in detail